This company has been marked as potentially delisted and may not be actively trading. Audentes Therapeutics (BOLD) Competitors Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsCompetitorsEarningsHeadlinesInsider TradesOwnershipShort InterestTrendsBuy This Stock BOLD vs. HURA, NBTX, OGI, DMAC, NLTX, PRQR, ACIU, TNGX, ESPR, and PBYIShould you be buying Audentes Therapeutics stock or one of its competitors? The main competitors of Audentes Therapeutics include TuHURA Biosciences (HURA), Nanobiotix (NBTX), Organigram (OGI), DiaMedica Therapeutics (DMAC), Neoleukin Therapeutics (NLTX), ProQR Therapeutics (PRQR), AC Immune (ACIU), Tango Therapeutics (TNGX), Esperion Therapeutics (ESPR), and Puma Biotechnology (PBYI). These companies are all part of the "pharmaceutical preparations" industry. Audentes Therapeutics vs. TuHURA Biosciences Nanobiotix Organigram DiaMedica Therapeutics Neoleukin Therapeutics ProQR Therapeutics AC Immune Tango Therapeutics Esperion Therapeutics Puma Biotechnology TuHURA Biosciences (NASDAQ:HURA) and Audentes Therapeutics (NASDAQ:BOLD) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their community ranking, analyst recommendations, valuation, media sentiment, profitability, institutional ownership, risk, dividends and earnings. Does the MarketBeat Community prefer HURA or BOLD? Audentes Therapeutics received 465 more outperform votes than TuHURA Biosciences when rated by MarketBeat users. However, 100.00% of users gave TuHURA Biosciences an outperform vote while only 69.12% of users gave Audentes Therapeutics an outperform vote. CompanyUnderperformOutperformTuHURA BiosciencesOutperform Votes5100.00% Underperform VotesNo VotesAudentes TherapeuticsOutperform Votes47069.12% Underperform Votes21030.88% Does the media favor HURA or BOLD? In the previous week, TuHURA Biosciences had 17 more articles in the media than Audentes Therapeutics. MarketBeat recorded 18 mentions for TuHURA Biosciences and 1 mentions for Audentes Therapeutics. TuHURA Biosciences' average media sentiment score of 0.32 beat Audentes Therapeutics' score of 0.00 indicating that TuHURA Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TuHURA Biosciences 3 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Audentes Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals & insiders hold more shares of HURA or BOLD? 0.6% of TuHURA Biosciences shares are owned by institutional investors. 0.2% of TuHURA Biosciences shares are owned by company insiders. Comparatively, 5.3% of Audentes Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Is HURA or BOLD more profitable? TuHURA Biosciences' return on equity of 0.00% beat Audentes Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets TuHURA BiosciencesN/A N/A -152.88% Audentes Therapeutics N/A -321.10%-40.02% Do analysts recommend HURA or BOLD? TuHURA Biosciences presently has a consensus target price of $12.67, indicating a potential upside of 347.59%. Given TuHURA Biosciences' stronger consensus rating and higher probable upside, equities analysts plainly believe TuHURA Biosciences is more favorable than Audentes Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TuHURA Biosciences 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25Audentes Therapeutics 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has stronger valuation & earnings, HURA or BOLD? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTuHURA BiosciencesN/AN/A-$8.32MN/AN/AAudentes TherapeuticsN/AN/A-$49.43MN/AN/A SummaryTuHURA Biosciences beats Audentes Therapeutics on 10 of the 13 factors compared between the two stocks. Get Audentes Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BOLD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BOLD vs. The Competition Export to ExcelMetricAudentes TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$44.60M$6.46B$5.34B$8.31BDividend YieldN/A2.63%5.27%4.11%P/E RatioN/A8.4426.9819.60Price / SalesN/A258.46398.81136.58Price / CashN/A65.8538.3234.64Price / BookN/A6.416.774.50Net Income-$49.43M$143.95M$3.24B$248.60M Audentes Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BOLDAudentes Therapeutics0.25 of 5 stars$1.57-31.9%N/A-86.2%$44.60MN/A0.00207News CoverageGap UpHURATuHURA BiosciencesN/A$4.03+5.5%$12.67+214.3%N/A$176.03MN/A0.00N/ANews CoverageAnalyst RevisionNBTXNanobiotix1.6592 of 5 stars$3.61+8.4%$8.00+121.6%-42.4%$170.15M$-11,609,000.000.00100Gap UpOGIOrganigram0.3398 of 5 stars$1.27-1.2%N/A-24.7%$169.30M$166.12M-3.33860Positive NewsGap DownDMACDiaMedica Therapeutics1.4656 of 5 stars$3.93+2.6%$8.00+103.6%+41.0%$168.42MN/A-7.0220NLTXNeoleukin TherapeuticsN/A$17.70+20.2%N/A-45.1%$166.35MN/A-5.6990Gap DownHigh Trading VolumePRQRProQR Therapeutics3.5206 of 5 stars$1.58-0.6%$8.75+453.8%-11.2%$166.24M$18.91M-4.94180ACIUAC Immune2.5928 of 5 stars$1.62-0.6%$10.00+517.3%-52.3%$162.66M$28.30M-3.52140Positive NewsTNGXTango Therapeutics1.565 of 5 stars$1.42+8.4%$12.33+768.5%-73.4%$153.51M$42.07M-1.2090Gap DownESPREsperion Therapeutics3.5588 of 5 stars$0.77-3.1%$6.25+707.4%-62.9%$153.39M$259.57M-1.21200PBYIPuma Biotechnology3.5562 of 5 stars$3.03-0.3%$7.00+131.0%-19.3%$150.38M$230.47M6.31200Analyst Upgrade Related Companies and Tools Related Companies TuHURA Biosciences Competitors Nanobiotix Competitors Organigram Competitors DiaMedica Therapeutics Competitors Neoleukin Therapeutics Competitors ProQR Therapeutics Competitors AC Immune Competitors Tango Therapeutics Competitors Esperion Therapeutics Competitors Puma Biotechnology Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BOLD) was last updated on 5/25/2025 by MarketBeat.com Staff From Our PartnersGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredTrump’s Bitcoin Reserve is No Accident…Bitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Audentes Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Audentes Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy BOLD Stock Free BOLD Stock Alerts